Dr Lalchandani Labs Limited's board of directors has approved the detailed terms for its proposed rights issue of equity shares during a meeting held on January 20, 2026. The comprehensive approval follows earlier intimations from December 2025 and establishes the framework for the company's capital raising initiative.

Rights Issue Structure and Pricing

The board approved the issuance of 43.32 lakh fully paid-up equity shares with a face value of ₹10.00 each. The rights issue is priced at ₹10.00 per share, matching the face value, with the entire issue price payable at the time of application.

Timeline and Key Dates

The company has established a comprehensive schedule for the rights issue process. The record date for determining eligible shareholders is set for January 27, 2026, with the issue opening on February 4, 2026.

The board retains the right to extend the issue period, though it cannot remain open for more than 30 days from the opening date. No withdrawal of applications will be permitted after the issue closing date.

Share Capital Impact

The rights issue will significantly impact the company's equity structure. Currently, Dr Lalchandani Labs has 43.33 lakh outstanding fully paid-up equity shares of ₹10.00 face value each.

Assuming full subscription and payment, the total outstanding equity shares will reach 86.65 lakh shares, effectively doubling the company's equity base.

Regulatory Compliance and Process

The company has initiated the process for obtaining an International Securities Identification Number (ISIN) for the rights entitlements from depositories. This ISIN will be disclosed in the Letter of Offer once received. In compliance with SEBI Master Circular dated November 11, 2024, Dr Lalchandani Labs has arranged with NSDL and CDSL for crediting Rights Entitlements in dematerialized form to eligible shareholders' demat accounts. The Rights Entitlements will be credited before the issue opening date under the designated ISIN.

The board meeting commenced at 5:00 PM and concluded at 5:50 PM on January 20, 2026, with Managing Director Arjan Lalchandani (DIN: 07014579) signing the regulatory filing.

Dr Lalchandani Labs Limited has received BSE in-principle approval for its proposed rights issue and continues to advance its ₹433.31 lakh fundraising initiative through equity shares with a face value of ₹10 each. The healthcare sector company has achieved a significant milestone in its capital raising process with regulatory clearance from the stock exchange.

BSE In-Principle Approval Received

The company received BSE Limited's in-principle approval on January 16, 2026, through reference number LOD/Rights/RB/FIP/1544/2025-26. The approval permits the company to use BSE Limited's name in its Letter of Offer for the proposed rights issue of fully paid-up equity shares.

Rights Issue Framework and Compliance Requirements

The BSE approval comes with specific compliance requirements and regulatory conditions. The exchange has granted permission for listing of fully paid-up equity shares proposed to be issued on rights basis, subject to completing post-issue requirements and complying with necessary statutory, legal and listing formalities.

Previous Board Meeting Outcomes

The board of directors had convened and held its meeting on December 15, 2025, from 4:00 PM to 5:00 PM, approving the fundraising initiative through rights issue mechanism. The company had initially scheduled the board meeting for December 9, 2025, which was subsequently deferred to December 15, 2025. Following the initial approval, the company scheduled another board meeting on December 22, 2025, to finalize the specific terms of the rights issue.

Regulatory Compliance and Next Steps

The BSE approval letter outlines several key compliance requirements including fixing a record date with at least three working days advance notice to the exchange. The company must disclose and intimate the rights issue price of equity shares at least three working days prior to the record date. The exchange has emphasized that the company will be solely responsible for any consequence arising due to non-disclosure, suppression or mis-statement of information in the offer document.

The rights issue remains subject to receipt of statutory and regulatory approvals in accordance with the amended SEBI regulations and other applicable laws. All requisite regulatory approvals will be obtained as required under the applicable framework.